Search alternatives:
release processes » decrease processes (Expand search), related processes (Expand search), disease processes (Expand search)
decrease release » decreases disease (Expand search), decrease renal (Expand search), protease release (Expand search)
decrease during » increase during (Expand search), increases during (Expand search), increased during (Expand search)
during action » during active (Expand search), during lactation (Expand search), during accretion (Expand search)
decrease not » decrease of (Expand search), decrease akt (Expand search), decrease at (Expand search)
not decrease » to decrease (Expand search), not increase (Expand search), and decrease (Expand search)
in decrease » in decreased (Expand search), on decrease (Expand search), pain decrease (Expand search)
release processes » decrease processes (Expand search), related processes (Expand search), disease processes (Expand search)
decrease release » decreases disease (Expand search), decrease renal (Expand search), protease release (Expand search)
decrease during » increase during (Expand search), increases during (Expand search), increased during (Expand search)
during action » during active (Expand search), during lactation (Expand search), during accretion (Expand search)
decrease not » decrease of (Expand search), decrease akt (Expand search), decrease at (Expand search)
not decrease » to decrease (Expand search), not increase (Expand search), and decrease (Expand search)
in decrease » in decreased (Expand search), on decrease (Expand search), pain decrease (Expand search)
1
“... of 1.8 cineoleee, remaining thus during 60min of monitorization (87.9±7.7; 87.6±7.1; 87.9±6.4; 87.8±5.7; 86.0...”
Access document
Access document
Article
2
“...The inability to wait for a target before initiating an action (i.e., waiting impulsivity) is one...”
Access document
Access document
Article
3
“...The inability to wait for a target before initiating an action (i.e., waiting impulsivity) is one...”
Access document
Access document
Article
4
“...The inability to wait for a target before initiating an action (i.e., waiting impulsivity) is one...”
Access document
Access document
Article
5
6
“... is known to reduce the intensity of Trypanosoma cruzi infections in mice even during a course of therapy...”
Access document
Access document
Article
7
“... in comparison to baseline responses. The minority of cells either increased spiking (~20%) or did not respond...”
Access document
Access document
Article
8
9
Treatment with tacrolimus enhances alveolar bone formation and decreases osteoclast number in the...
“... accounting for this action is unclear at present. In the present study, we attempted to determine the effect...”Access document
Article
10
“..., as are serum lipid levels in the Peg-IFN / RBV-based treatment. However, with direct action antivirals...”
Access document
Access document
Article
11
“... lipid levels in the Peg-IFN/RBV-based treatment. However, with direct action antivirals (DAAs) this...”
Access document (1)
Access document (2)
Access document (1)
Access document (2)
Article
12
“..., we demonstrated that part of the postprandial tachycardia can be ascribed to a progressive decrease...”
Access document
Access document
Article
13
“..., we demonstrated that part of the postprandial tachycardia can be ascribed to a progressive decrease...”
Access document (1)
Access document (2)
Access document (1)
Access document (2)
Article
14
15
“.... Female authors have faced a decrease in paper submission rates since the beginning of the pandemic period...”
Access document
Access document
Article
16
17
“... (GH) during Nellore heifer’s sexual maturation. The animals were randomly assigned into two experimental...”
Access document
Access document
Article
18
“... (GH) during Nellore heifer's sexual maturation. The animals were randomly assigned into two experimental...”
Access document
Access document
Article
19
“... veins were formed during dextral strike–slip faulting. Both vein systems are formed essentially...”
Access document
Access document
Article
20
“... innovative properties that they can offer to, e.g., the end-use industry or biomedicine. The release of NMs...”
Access document
Access document